OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Consensus Rating of “Hold” by Brokerages

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has been given an average recommendation of “Hold” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.3333.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research note on Tuesday, April 21st.

OKYO Pharma Stock Performance

NASDAQ:OKYO opened at $1.50 on Thursday. The stock has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $1.79. OKYO Pharma has a 52-week low of $1.42 and a 52-week high of $3.35.

Institutional Investors Weigh In On OKYO Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in OKYO Pharma during the third quarter valued at approximately $31,000. XTX Topco Ltd bought a new stake in shares of OKYO Pharma during the 4th quarter worth approximately $36,000. Finally, Renaissance Technologies LLC raised its stake in shares of OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares in the last quarter. 2.97% of the stock is owned by institutional investors.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.